Fluvoxamine Attenuates Panic Induced by 35% CO2 Challenge
J Clin Psychiatry 1996;57(11):539-542
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Background: The authors investigated whether 6 weeks of treatment with fluvoxamine would decrease the anxiogenic response to the 35% CO2 challenge in 11 patients with DSM-IIIR panic disorder with agoraphobia.
Method: The patients underwent a 35% CO2 challenge at baseline and again after 6 weeks of fluvoxamine treatment.
Results: The anxiogenic effect of CO2 was significantly (p < .05) reduced during fluvoxamine treatment.
Conclusion: The results suggest a relationship between the anxiogenic effect of CO2 and the therapeutic effect of fluvoxamine.